On such a substrate, levetiracetam’s broad presynaptic reduction of transmitter release at both excitatory and inhibitory terminals (via SV2A) may further depress the already unstable swallow CPG output, aggravating dysphagia until the drug is withdrawn (25, 27). The gene discussed is SV2A; the disease is Dysphagia.